
Before we can intelligently set the limits of process variation, we need to know what the clinical impact of that variation will be.
Douglas McCormick is a former Editor-in-Chief of Pharmaceutical Technology.

Before we can intelligently set the limits of process variation, we need to know what the clinical impact of that variation will be.

We, the people who make drugs, are extraordinarily good at what we do.

Ninety million people live in California, Texas, New York, and Florida. Imagine that, sometime tonight, an unnameable catastrophe carries off everyone in those states over the age of 14. When the sun comes up tomorrow, only the children remain. Eighteen million children, left to care for one another or fend for themselves.

ePT--the Electronic Newsletter of Pharmaceutical Technology
Sun Pharma Buys US, Hungarian Drug Plants from Valeant

March 2nd 2007

February 2nd 2007

September 15th 2005

January 2nd 2007